Investing in research may not be sexy and may not provide immediate gratification, but it’s vital to the discovery of better treatments and cures.
Your donations fund the research that explores why children develop brain tumors, how to improve care and produce better outcomes. Because of you, we’re changing the landscape of pediatric cancer.
Pediatric cancer research is 15 years behind adult cancer research. Our kids are our future and worth more! Research has improved care and led to some better outcomes for kids, but there is so much more that needs to be done.
KRF invests in research where experts from various disciplines are collaborating, sharing data and specimens to accelerate discovery and reduce the duplication of efforts. We’ve raised close to two million dollars in the past twelve years for the pursuit of improving the lives of children with brain tumors.
Supporting research doesn’t’ bring immediate satisfaction. It may take years of research to truly understand the causes of brain tumors and discover better treatments and cures. But funding the collaboration of researchers around the world so they can share their failures and successes is vital and made possible with your donations to The Kortney Rose Foundation.
“The past decade has witnessed the emergence of entirely new technologies in biomedicine that provide for the ﬁrst time the opportunity for new precision medicine approaches to treat cancer. However, applying these discoveries towards cures for children with brain tumors faces numerous challenges ranging from limited funding for research to the need for increased advocacy and education of patients and families. The KRF, through an unparalleled grass roots eﬀort, has served to uniquely empower the discovery of new precision medicine approaches for kids with brain tumors through their support of the Children’s Brain Tumor Tissue Consortium, a collaborative network of pediatric hospitals dedicated to open access, data-driven discoveries in pediatric cancer.”
Dr. Adam Resnick
Director of Data Driven Discovery in Biomedicine (D3b) at CHOP